← brief for 2026-11-02 · Slowing decline

Cardiovascular-kidney-metabolic syndrome: conceptual framework, clinical implications, and therapeutic perspectives with a focus on SGLT2 inhibitors.

Paper No results yet Peer reviewed

Key takeaways

This review explains how heart, kidney, and metabolic health are connected. It focuses on a class of drugs called SGLT2 inhibitors. It discusses how these drugs may help manage this combined condition. It is a review of existing knowledge, not a new trial.

Who did this work

Uyaroglu OA · Adas M · Altun B · Temizhan A · Tukek T · Arı Bakır E · Yıldırımtürk O · Ukinç K

Source

Paper · PubMed, the drug frontier · 2026 Nov 1
https://pubmed.ncbi.nlm.nih.gov/42968538/